November 7, 2019
Nippon Shinyaku’s oligonucleotide Duchenne muscular dystrophy (DMD) drug viltolarsen was designated for Japan’s conditional early approval scheme, the company said on November 6, making it the third product to which the system was applied since its introduction in 2017. Under...read more